Sai Life Sciences (NSE:SAILIFE) Debt-to-Equity: N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
19 GF Score
Price ₹1,485.00
! 4 Warning Signs
View Full Analysis

What is Sai Life Sciences Debt-to-Equity?

Sai Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Sai Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Sai Life Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sai Life Sciences's Debt-to-Equity or its related term are showing as below:

NSE:SAILIFE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12   Med: 0.95   Max: 1.1
Current: 0.12

During the past 5 years, the highest Debt-to-Equity Ratio of Sai Life Sciences was 1.10. The lowest was 0.12. And the median was 0.95.

NSE:SAILIFE's Debt-to-Equity is ranked better than
68.89% of 180 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.275 vs NSE:SAILIFE: 0.12

Sai Life Sciences  (NSE:SAILIFE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sai Life Sciences Debt-to-Equity Related Terms

Sai Life Sciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences Debt-to-Equity Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Equity
1.10 1.05 0.95 0.17 0.12

Sai Life Sciences Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.18 N/A 0.12 N/A

NSE:SAILIFE vs TMO, DHR, IDXX: Debt-to-Equity Comparison

For the Diagnostics & Research subindustry, Sai Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sai Life Sciences Debt-to-Equity vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sai Life Sciences's Debt-to-Equity falls into.


NSE:SAILIFE
19GF Score
Sai Life Sciences Ltd NSE:SAILIFE
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sai Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1403.28 + 1481.24) / 24836.88
=0.12

Sai Life Sciences's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
19GF Score

Get the complete analysis for NSE:SAILIFE

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,485.00
Price